The importance of serial #ctDNA monitoring in #MBC @CCR_AACR. Really enjoyed helping to mentor Saya Jacob @NU_IntMed. A rising star that @UCSFCancer will be lucky to have!
This Post is from an account that no longer exists. Learn more
Andrew Davis retweeted
The organ tropism of #Metastatic #BreastCancer derives by multiple #liquidbiopsy features. Intriguing associations: #ESR1, #CTC with bone/liver involvement, #PIK3CA with lung. First steps towards a #PrecisionMedicine monitoring algorithm? #ctDNA #bcsm #MBC ejcancer.com/article/S0959-8…
Andrew Davis retweeted
Registration is now OPEN! 10/20 630pm CT IPC Breast Cancer with chair Cynthia X. Ma, MD, PhD @WUSTLmed. Join our Breast Cancer experts @KatherineClift4 @AndrewDavisMD Nusayba A. Bagegni, MD Mateusz Opyrchal, MD, PhD #bcsm #oncLiveIPC @OncLiveSOSS ow.ly/uSyM50BJXu1
Andrew Davis retweeted
Excellent editorial on the role of MRD after preop therapy for TNBC @MCristofanill
Our work under the great mentorship of @MCristofanill published in @EBioMedicine. #ctDNA in #MBC captures tumor heterogeneity across subtypes and identifies clinically relevant alterations. @LGerratana @LeonidasPlatan1 @DrWGradishar @AmirBehdadMD
authors.elsevier.com/sd/arti…
Excited to work with friends and colleagues as a guest editor for an upcoming issue of @FrontiersIn. Please consider submitting a manuscript to our research topic!
Thrilled to announce a new editorial project co-edited with Marco Mina and @AndrewDavisMD focused on cutting edge manuscripts examining clinically relevant aspects of #cancer evolution. @FrontiersIn #PrecisionMedicine #NGS #Genomics frontiersin.org/research-top…
Andrew Davis retweeted
Editorial w paper on significant assoc'n between detected circulating tumor DNA (ctDNA) &/or circ’g tumor cells (CTCs) & outcomes after neoadj chemo & surgery for early stage triple neg #BreastCancer reviews current data & new directions for research ja.ma/2W2oJYy #BCSM
Our @JAMAOnc editorial out today. #liquidbiopsy #MRD is the future, but important research questions remain.
This Post is from an account that no longer exists. Learn more
Thank you @NUFeinbergMed @LurieCancer @NorthwesternMed for a wonderful 10 years. Ready to begin my next adventure as assistant professor @WUSTLmed @SitemanCenter
Andrew Davis retweeted
BREAKING: Trastuzumab deruxtecan was granted an accelerated approval for the treatment of adult patients with unresectable/metastatic HER2+ breast cancer who have received ≥2 prior lines of anti–HER2-based regimens in the metastatic setting.
targetedonc.com/news/trastuz… #BreastCancer
Andrew Davis retweeted
#JITC Short Report: The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors jitc.biomedcentral.com/artic…
Proud of my uncle for publishing in @NEJM. A great role model for a physician scientist. @MoranEyeCenter
Macular telangiectasia is an etiologically complex phenotype. This study used a combination of approaches to identify both genetic and environmental risk factors for the disease, both of which affect lipid metabolism. nej.md/311sk8P
Excellent collaboration and team effort. Very excited about our work moving forward.
It was an honor to be selected by @rdienstmann, a pioneer and thought leader in this field. #ESMO2019 #ESMO19 #cfDNA. Great collaboration with @NUFeinbergMed @lexentbio
Andrew Davis retweeted
Important perspective, but in an era of transformative team science, one does not need to pipette, work with mice or zebrafish or be R01-funded to be an impactful physician-researcher. Maybe we need to redefine who we consider to be a "scientist".
We Need More Doctors Who Are Scientists nyti.ms/2mAvMZD
Andrew Davis retweeted
Our preprint is now available on @medrxivpreprint: Early detection of molecular disease progression by whole-genome circulating tumor DNA in advanced solid tumors medrxiv.org/content/10.1101/…
Andrew Davis retweeted
Solid and liquid-based #genomics are becoming part of #clinicalpractice but, notwithstanding their potential, these technologies may have caveats that need to be taken into consideration for a correct #data interpretation. #MBC #ctDNA #PrecisionMedicine link.springer.com/article/10…
Honored to be a part of this international collaboration. Emphasizing the importance of Stage IV indolent and Stage IV aggressive #breastcancer. #bcsm
Circulating tumor cell #CTC count should be considered an important tool for staging of metastatic #breastcancer and for disease stratification in prospective #clinicaltrials: @MCristofanill sciencedirect.com/science/ar…
Appreciate the opportunity to interview with @TargetedOnc about #PrecisionMedicine
Our Hem/Onc Fellow, Andrew Davis, MD, on Quantifying the Benefits of Precision Oncology shar.es/aaJRGu via @TargetedOnc @NorthwesternMed @NU_IntMed #PrecisionMedicine